Lenograstim 33.6million unit powder and solvent for solution for injection pre-filled syringes
Requires a prescription from a doctor or prescriber
Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Lenograstim
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Lenograstim on the MHRA register
Granocyte 34million unit powder and solvent for solution for injection pre-filled syringes
WHO defined daily dose (DDD)
350 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Lenograstim
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2.3 - 3.3 hrs
Mechanism
Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
2.3 - 3.3 hrs
Volume of distribution
5 mL
Metabolism
Elimination
1%
Clearance
150 mL/min
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy.
Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion.
GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).
Known interactions with other medications. Always consult a healthcare professional.
Showing 9 of 9 interactions
Test type: TDLo ( Lowest Published Toxic Dose)
Route of exposure: Subcutaneous
Dose/Duration: 21428mg/kg/15
Toxic Effect:
Skin and appendages: Dermatitis, allergic ( after systemic exposure )
Species observed : Rodent - Rat
Test type: LD50
Route of exposure: Oral
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value
Species observed : Rodent - Rat
Test type: LD50
Route of exposure: Subcutaneous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value
Species observed : Rodent - Rat
Test type: LD50
Route of exposure: Intravenous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value
Species observed : Mammal - Dog
Test type: LD50
Route of exposure: Intravenous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value
Species observed : Mammal - Dog
Test type: LD50
Route of exposure: Subcutaneous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
ATC L03AA10
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Lenograstim
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: